SRRK | tickerfilter.com

Fundamental analysis

23%

Profitability 25%

Dept financing 9%

Liquidity 50%

Performance 18%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.64%

1 Month

22.94%

3 Months

426.71%

6 Months

481.12%

1 Year

137.42%

2 Year

471.64%

Key data

Stock price

$45.20

P/E Ratio

0.00

DAY RANGE

$44.44 - $45.76

EPS

$0.00

52 WEEK RANGE

$7.40 - $46.18

52 WEEK CHANGE

$124.21

MARKET CAP

744.303 M

YIELD

N/A

SHARES OUTSTANDING

80.033 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/05/2024

BETA

1.34

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,196,123

AVERAGE 30 VOLUME

$1,024,049

Company detail

CEO: Jay T. Backstrom
Region: US
Website: scholarrock.com
Employees: 140
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Scholar Rock Holding Corporation focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin, and SRK-181, which is in Phase 1 clinical trials. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients.

SRRK - Scholar Rock Holding Corp